SNDX
Syndax Pharmaceuticals IncPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 6 to Feb 9 ▼ 2 days of insider sells: $628.3K by 2 insiders, avg $20.90
- Jun 1 ▼ 2 insiders sell $152.4K at $18.99
- Jun 11 to Jun 12 ▼ 2 days of insider sells: $1.2M by 1 insider, avg $18.07
- Jun 11 ▲ Syndax presented 12 abstracts on revumenib at EHA 2026, including re…
- Jul 8 ▼ 1 insider sell $784.8K at $24.24
- Jul 14 ▲ Syndax held an R&D event unveiling two new pipeline assets: SNDX-432…
- Oct 29 ▼ 1 insider sell $113.7K at $14.21
- Nov 2 ▼ Earnings: SNDX Q3 2026 Earnings: EPS $-0.55 (-9.6% vs est)
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $2.9M.
- InstitutionsMIXED
Q3 2026: 23 added (1 new), 20 trimmed or exited.
- AnalystsBULLISH
17 of 18 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +5.1% to 18.92M shares. 6.4 days to cover, ≈21.0% of shares.
- TrendDOWNTREND
39% below its 50-day average. New closing low $9.13 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Aberdeen Group plc | NEAR_EXIT | $36.6M |
| FRANKLIN TEMPLETON INC | ADD | $36.4M |
| LOOMIS SAYLES & CO L P | ADD | $25.1M |
| UBS Group AG | TRIM | $21.5M |
| Nuveen, LLC | TRIM | $16.1M |
| HRT FINANCIAL LP | ADD | $11.5M |
| Jump Financial, LLC | ADD | $10.0M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $3.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
18 analystsPrice is below the lowest target. Median implies +294%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 3, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 13, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 21, 2026 | UBS MAINTAIN | Buy |
| Aug 11, 2026 | JP Morgan MAINTAIN | Overweight |
| Aug 5, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Jul 15, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Ondrey Aaron Chief Financial Officer Nov 9, 2026 | AWARD | $2.6M |
Podlesak Dennis Director Oct 29, 2026 | SELL | $113.7K |
Podlesak Dennis Director Oct 29, 2026 | EXERCISE | $94.5K |
Metzger Michael A Chief Executive Officer Jul 8, 2026 | SELL | $784.8K |
Metzger Michael A Chief Executive Officer Jul 8, 2026 | EXERCISE | $206.6K |
Botwood Nicholas A.J. Head of R&D, CMO Jun 12, 2026 | EXERCISE | $431.7K |
Botwood Nicholas A.J. Head of R&D, CMO Jun 12, 2026 | SELL | $566.6K |
Botwood Nicholas A.J. Head of R&D, CMO Jun 11, 2026 | EXERCISE | $311.2K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | -$2.13 | -$2.24–-$1.96 | -9.0% | $316.4M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 3 press releases · 1 bullish · 0 bearish · 12 neutral- NEUTRAL 3Nov 12, 2026
Aaron Ondrey filed a Form 3 initial statement of beneficial ownership after becoming Chief…
Monitor for any subsequent Form 4 filings that may indicate insider buying or selling by the new CFO, which could signal conviction in the company's outlook.
- NEUTRAL SC 13GNov 10, 2026
State Street Corp filed a Schedule 13G disclosing a 5.2% passive stake in Syndax Pharmaceuticals…
State Street's passive stake increase is routine for a large index fund manager. Monitor the next 13F filing for any material changes in institutional positioning, but this filing alone does not…
- NEUTRAL PRESS-RELEASENov 9, 2026
Syndax Pharmaceuticals issued a press release announcing an inducement stock option award of…
This is a standard inducement grant for a new executive hire. No financial results or guidance were released. Monitor the next quarterly filing for any operational updates or changes in strategy…
- NEUTRAL 8-KNov 2, 2026
Syndax reported Q3 2026 total revenue of $83.3M (82% YoY growth), beating the $81.8M consensus…
Revenue growth is strong and accelerating, but the EPS miss and the failed IPF trial introduce caution. Watch for upcoming revumenib data at medical meetings in Q4 2026, particularly from frontline…
All SNDX filing & press-release reports (16)
- 3 reportNov 12, 2026
- SC 13G reportNov 10, 2026
- PRESS-RELEASE reportNov 9, 2026
- 8-K reportNov 2, 2026
- PRESS-RELEASE reportNov 2, 2026
- PRESS-RELEASE reportNov 2, 2026
- 144 reportOct 29, 2026
- 8-K reportJul 14, 2026
- PRESS-RELEASE reportJul 1, 2026
- PRESS-RELEASE reportJun 11, 2026
- 8-K reportJun 10, 2026
- PRESS-RELEASE reportJun 4, 2026
- DEFA14A reportJun 4, 2026
- 8-K reportJun 4, 2026
- DEFA14A reportApr 30, 2026
- PRESS-RELEASE reportApr 24, 2026